A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).
V. Dieras
Honoraria - Amgen
J. Jassem
No relevant relationships to disclose
L. Y. Dirix
No relevant relationships to disclose
J. P. Guastalla
Honoraria - Amgen
P. Bono
No relevant relationships to disclose
S. A. Hurvitz
Honoraria - Roche/Genentech
A. Gonçalves
No relevant relationships to disclose
G. Romieu
No relevant relationships to disclose
S. A. Limentani
Research Funding - Amgen
G. H. M. Jerusalem
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
K. Lakshmaiah
No relevant relationships to disclose
H. H. Roche
Honoraria - Bristol-Myers Squibb
P. Sánchez-Rovira
No relevant relationships to disclose
T. Pienkowski
Honoraria - Roche
Research Funding - Roche
M. A. Seguí-Palmer
No relevant relationships to disclose
A. Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. Sun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. A. Pickett-Gies
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Wildiers
Consultant or Advisory Role - Amgen
Honoraria - Amgen